Pengchao Tian

Pengchao Tian

Auto-generated profile, based on publicly available information

Pengchao Tian

Department of Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
YWYihang Wu
Yihang Wu
PTPengchao Tian
Pengchao Tian
LLLin Liang
Lin Liang
YCYuyi Chen
Yuyi Chen
JFJiayu Feng
Jiayu Feng
ZJzhang jian
zhang jian
Right ventricular (RV)‐pulmonary arterial uncoupling is the consequence of increased afterload and/or decreased RV contractility. However, the combination of arterial elastance (Ea) and end‐systolic elastance (Ees)/Ea ratio to assess RV function is unclear. We hypothesized that the combination of both could comprehensively assess RV function and refine risk stratification. The median Ees/Ea ratio (0.80) and Ea (0.59 mmHg/mL) were used to classify 124 patients with advanced heart failure into four groups. RV systolic pressure differential was defined as end‐systolic pressure (ESP) minus beginning‐systolic pressure (BSP). Patients among different subsets showed dissimilar New York Heart Association functional class (V = 0.303, p = 0.010), distinct tricuspid annular plane systolic excursion/ pulmonary artery systolic pressure (mm/mmHg; 0.65 vs. 0.44 vs. 0.32 vs. 0.26, p < 0.001), and diverse prevalence of pulmonary hypertension (33.3% vs. 35% vs. 90% vs. 97.6%, p < 0.001). By multivariate analysis, Ees/Ea ratio (hazard ratio [HR] 0.225, p = 0.004) and Ea (HR 2.194, p = 0.003) were independently associated with event‐free survival. Patients with Ees/Ea ratio greater than or equal to 0.80 and Ea less than 0.59 mmHg/mL had better outcomes (p < 0.05). In patients with Ees/Ea ratio greater than or equal to 0.80, those with Ea greater than or equal to 0.59 mmHg/mL had a higher adverse outcome risk (p < 0.05). Ees/Ea ratio less than or equal to 0.80 was associated with adverse outcomes, even when Ea was less than 0.59 mmHg/mL (p < 0.05). Approximately 86% of patients with ESP‐BSP greater than 5 mmHg had an Ees/Ea ratio less than or equal to 0.80 and/or an Ea greater than or equal to 0.59 mmHg/mL (V = 0.336, p = 0.001). Combined use of Ees/Ea ratio and Ea could be a comprehensive approach to assessing RV function and predicting outcomes. An exploratory analysis demonstrated that Ees/Ea ratio and Ea might be roughly estimated based on RV systolic pressure differential.

28 August 2026 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
JZJin Zhang
Jin Zhang
PTPengchao Tian
Pengchao Tian
JWJingyi Wang
Jingyi Wang
WLWenxiong Li
Wenxiong Li
NCNa Cui
Na Cui
Sepsis-associated acute kidney injury (SA-AKI) is a frequent and high-mortality complication in critically ill patients. Current diagnostic criteria rely on functional markers that often lag behind the onset of renal injury. While immune dysregulation is central to SA-AKI pathogenesis, few prediction models systematically integrate multidimensional immune phenotypes. The present analysis was based on a multicenter prospective cohort study involving 1,551 septic patients. The study was carried out across five tertiary hospitals in Beijing. Clinical data and immuno-inflammatory biomarkers (including humoral, complement, and T lymphocyte subsets) were collected within 24 hours of sepsis diagnosis. An Extreme Gradient Boosting (XGBoost) model was then developed to predict SA-AKI. New-onset SA-AKI occurred in 44.8% of the cohort and was associated with increased mortality. We identified a distinct high-risk immuno-inflammatory endotype characterized by elevated immunoglobulin A and procalcitonin (PCT), consumptive complement component 3 depletion, and a "complex and divergent cellular immune pattern"-manifested as depleted naïve CD4+ T cells coexisting with expanded CD28+CD4+ T cells. Integrating these immune features with routine clinical variables (Acute Physiology and Chronic Health Evaluation II (APACHE II), the Sequential Organ Failure Assessment [SOFA], PCT, prothrombin time [PT], sex) yielded an XGBoost-based clinical-immune model with superior discrimination (area under the curve [AUC], 0.914), significantly outperforming the clinical model (AUC, 0.788). Decision curve analysis further confirmed greater net clinical benefit for the integrated model. Immune dysregulation plays an important role in developing AKI in sepsis patients. Immune biomarkers could significantly improve early identification of high SA-AKI risk patients.

14 August 2026 in JMIR Medical Informatics
Verified
Journal Article
Open access
FLFei Li
Fei Li
XGXiaoxia Guo
Xiaoxia Guo
YLYunhao Li
Yunhao Li
JZJin Zhang
Jin Zhang
JWJingyi Wang
Jingyi Wang
NCNa Cui
Na Cui
Background: Sepsis-associated acute kidney injury (SA-AKI) is a frequent and life-threatening complication of sepsis. While the static lactate-to-albumin ratio (LAR) has prognostic value, its dynamic temporal evolution during early resuscitation and its utility for guiding clinical risk stratification remain underexplored. Objective: The aim of the study is to identify distinct dynamic trajectories of LAR, evaluate their independent associations with adverse clinical outcomes, and construct a practical prognostic nomogram for patients with SA-AKI. Methods: Data were extracted from the Medical Information Mart for Intensive Care IV database, including adult patients with SA-AKI and ≥ 3 lactate and albumin measurements within the first 72 hours of intensive care unit admission. A multicenter external validation cohort was assembled from 5 tertiary hospitals in Beijing, China. Group-based trajectory modeling identified distinct LAR trajectories. The primary outcome was 28-day mortality; secondary outcomes included 90-day mortality and continuous renal replacement therapy initiation. Trajectory-outcome associations were assessed using multivariable Cox and logistic regression models. Robustness was examined using restricted cubic splines, inverse probability of treatment weighting, weight truncation, doubly robust estimation, and subgroup analyses. Incremental predictive value beyond single baseline LAR was quantified, and a trajectory-integrated nomogram was developed and externally validated. Results: Among the 615 patients in the primary cohort, 3 LAR trajectories were identified: trajectory 1 (low-stable type), trajectory 2 (rapid-clearance type), and trajectory 3 (delayed-clearance type). In adjusted multivariable models, trajectory 3 (vs trajectory 1) was independently associated with increased 28-day mortality risk (hazard ratio 1.63, 95% CI 1.00‐2.64; P =.0496), 90-day mortality (hazard ratio 1.72, 95% CI 1.14‐2.60; P =.01), and continuous renal replacement therapy initiation (odds ratio 3.40, 95% CI 1.64‐7.15; P =.001). Conversely, the mortality risk for trajectory 2 did not differ significantly from trajectory 1. Sensitivity analyses supported these findings, although trajectory 3 associations attenuated in inverse probability of treatment weighting–weighted analyses. Incorporating trajectories improved predictive accuracy over single baseline LAR (continuous net reclassification improvement 0.170, integrated discrimination improvement 0.023; both P =.01). In the external validation cohort (n=508), 3 analogous trajectories were identified. Trajectory 3 consistently conferred a higher mortality risk across both cohorts, whereas trajectory 2 was significantly associated with 28-day mortality only in validation. The nomogram exhibited modest discrimination in the external cohort (concordance index=0.612), acceptable calibration, and potential utility as a supplementary bedside risk stratification tool. Conclusions: Dynamic LAR trajectories are independently associated with 28- and 90-day mortality in SA-AKI. The delayed-clearance trajectory identifies a specific high-risk phenotype, suggesting that longitudinal LAR monitoring and the constructed nomogram may support early risk stratification and inform clinical decision-making.